Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 46, Issue 4, 2011, Pages 529-535

  Kobayashi, Yumi ^a   Kawaguchi, Yasunori ^a   Mizuta, Toshihiko ^a   Kuwashiro, Takuya ^a   Oeda, Satoshi ^a   Oza, Noriko ^a   Takahashi, Hirokazu ^a   Iwane, Shinji ^a   Eguchi, Yuichiro ^a   Anzai, Keizo ^a   Ozaki, Iwata ^a   Fujimoto, Kazuma ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Alanine aminotransferase; Chronic hepatitis C; Hepatic steatosis; High density lipoprotein cholesterol; HOMA IR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID METABOLISM; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALANINE TRANSAMINASE; BIOPSY; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 79959836147     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0338-x     Document Type: Article

References (42)

1. Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:1-52.
2. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002;137:961-4. (Pubitemid 35440242)
3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-100.
4. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825-32.
5. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-56.
6. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol. 2001;32:904-9. (Pubitemid 32911311)
7. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1251-9.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-64. (Pubitemid 32496971)
9. Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82-7. (Pubitemid 40066385)
10. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, HCV meta-analysis (on) Individual Patients' Data Study Group, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636-42.
11. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279-83. (Pubitemid 32803485)
12. Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis. Hepatology. 2006;43:64-71. (Pubitemid 43738959)
13. Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T, et al. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinemia in patients with chronic hepatitis C. Liver Int. 2009;29:871-7.
14. Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009;29:213-20.
15. Benvegnù L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology. 1997;25:211-5. (Pubitemid 27015012)
16. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78:1527-31. (Pubitemid 27343089)
17. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatic C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840-8. (Pubitemid 38298332)
18. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065-7. (Pubitemid 28417341)
19. Alberti A. Towards more individualized management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. J Hepatol. 2005;42:266-74. (Pubitemid 40143475)
20. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266-71. (Pubitemid 30235957)
21. Craxì A, Almasio P. Diagnostic approach to liver enzyme elevation. J Hepatol. 1996;25(Suppl 1):47-51. (Pubitemid 26278412)
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9. (Pubitemid 15018832)
24. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323-35.
25. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-70.
26. Ohno T, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201-7. (Pubitemid 26422655)
27. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, et al. Abdominal fat: standardized technique for measurement at CT. Radiology. 1999;211:283-6. (Pubitemid 29161765)
28. Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-93.
29. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
30. Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol. 2006;44:679-85.
31. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213-9.
32. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766-71. (Pubitemid 29513577)
33. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9:1089-97. (Erratum in: Nat Cell Biol. 2007; 9:1216).
34. Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat. 2006;13:56-61.
35. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med. 2007;120:S3-8.
36. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462-9. (Pubitemid 43941913)
37. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102:2108-13.
38. Bonkovsky H, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-68.
39. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 1994;89:986-8. (Pubitemid 24201831)
40. Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol. 2004;39:570-4. (Pubitemid 38996900)
41. Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Tanaka E, Kiyosawa K. Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study. J Gastroenterol. 2007;42:49-55. (Pubitemid 46351424)
42. Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Yokoyama T, Okaniwa S, et al. Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections. J Gastroenterol. 2009;44:577-82.